DICE Therapeutics, Inc.
DICE · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $73 | $102 | $461 | $48 |
| Short-Term Investments | $455 | $453 | $113 | $218 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $5 | $4 | $1 |
| Total Curr. Assets | $532 | $559 | $578 | $268 |
| Property Plant & Equip (Net) | $17 | $16 | $16 | $16 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $0 | $0 | $1 |
| Total NC Assets | $18 | $16 | $16 | $17 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $551 | $576 | $594 | $285 |
| Liabilities | – | – | – | – |
| Payables | $3 | $4 | $3 | $1 |
| Short-Term Debt | $2 | $1 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $16 | $12 | $11 | $9 |
| Total Curr. Liab. | $21 | $17 | $15 | $12 |
| LT Debt | $11 | $11 | $12 | $12 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $11 | $11 | $12 | $12 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $32 | $29 | $27 | $24 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$248 | -$213 | -$188 | -$164 |
| AOCI | $0 | -$0 | -$1 | -$1 |
| Other Equity | $767 | $0 | $1 | $427 |
| Total Equity | $519 | -$213 | -$188 | $261 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $551 | -$185 | -$161 | $285 |
| Net Debt | -$61 | -$89 | -$448 | -$35 |